Really good summary from the CEO:
http://www.openbriefing.com/OB/1937.aspx
Great to hear that the issue of shares will be at market price.
The only mystery with Cyclopharm is why they are restoring the loss making Cyclotron. While the restoration is covered by insurance, the ongoing cost is estimated at $43k per month, but this business unit has traditionally made heavy losses.
Ann: Cyclopharm signs Term Sheet with Jubilant Draximage, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
0.000(0.00%) |
Mkt cap ! $111.1M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 9381 | 2 |
View Market Depth
| Last trade - 10.02am 18/06/2025 (20 minute delay) ? |
| CYC (ASX) Chart |
Day chart unavailable